BR0312501A - Combinação de um inibidor alostérico ou metaloproteinase de matriz-13 com um inibidor de ciclooxigenase-2 diferente de celecoxib ou valdecoxib - Google Patents

Combinação de um inibidor alostérico ou metaloproteinase de matriz-13 com um inibidor de ciclooxigenase-2 diferente de celecoxib ou valdecoxib

Info

Publication number
BR0312501A
BR0312501A BR0312501-7A BR0312501A BR0312501A BR 0312501 A BR0312501 A BR 0312501A BR 0312501 A BR0312501 A BR 0312501A BR 0312501 A BR0312501 A BR 0312501A
Authority
BR
Brazil
Prior art keywords
inhibitor
valdecoxib
celecoxib
cyclooxygenase
matrix
Prior art date
Application number
BR0312501-7A
Other languages
English (en)
Inventor
Gerard Michael Meisel
Arthur Anthony Ciociola
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/193,475 external-priority patent/US20040009234A1/en
Priority claimed from US10/196,053 external-priority patent/US6986901B2/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0312501A publication Critical patent/BR0312501A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMBINAçãO DE UM INIBIDOR ALOSTéRICO OU METALOPROTEINASE DE MATRIZ-13 COM UM INIBIDOR DE CICLOOXIGENASE-2 DIFERENTE DE CELECOXIB OU VALDECOXIB". A presente invenção refere-se a composições e a métodos para o tratamento e/ou prevenção de distúrbios gastrointestinais (GI) inferiores em pacientes mamíferos, mais especificamente para o alívio e/ou prevenção dos sintomas GI inferiores que estão associados a esses distúrbios.
BR0312501-7A 2002-07-10 2003-06-30 Combinação de um inibidor alostérico ou metaloproteinase de matriz-13 com um inibidor de ciclooxigenase-2 diferente de celecoxib ou valdecoxib BR0312501A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/193,475 US20040009234A1 (en) 2002-07-10 2002-07-10 Gastrointestinal compositions
US10/196,053 US6986901B2 (en) 2002-07-15 2002-07-15 Gastrointestinal compositions
PCT/IB2003/003196 WO2004006902A1 (en) 2002-07-10 2003-06-30 Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib

Publications (1)

Publication Number Publication Date
BR0312501A true BR0312501A (pt) 2005-04-12

Family

ID=30117822

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312501-7A BR0312501A (pt) 2002-07-10 2003-06-30 Combinação de um inibidor alostérico ou metaloproteinase de matriz-13 com um inibidor de ciclooxigenase-2 diferente de celecoxib ou valdecoxib

Country Status (9)

Country Link
US (1) US20050136127A1 (pt)
EP (1) EP1531801A1 (pt)
JP (1) JP2005533101A (pt)
AU (1) AU2003281172A1 (pt)
BR (1) BR0312501A (pt)
CA (1) CA2491797A1 (pt)
MX (1) MXPA05000477A (pt)
NZ (1) NZ537395A (pt)
WO (1) WO2004006902A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005224061B2 (en) * 2004-03-19 2011-01-27 Solvay Pharmaceuticals Gmbh Use of a 5-HT3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
JP5421098B2 (ja) * 2006-06-06 2014-02-19 ジーアイケア ファーマ インク． トリメブチン及びｎ−脱メチル化トリメブチンの塩類
KR101132977B1 (ko) 2010-01-12 2012-04-09 삼일제약주식회사 트리메부틴 및 프로키네틱제를 함유하는 안정한 약학 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158538A (en) * 1961-02-23 1964-11-24 White Lab Inc Antidiarrheal compositions and method of using
US3257275A (en) * 1962-02-07 1966-06-21 Weisberg Mark Chitosan containing antacid composition and method of using same
FR2460919A1 (fr) * 1979-07-11 1981-01-30 Prod Synthese Ste Indle Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique
JPS5858146A (ja) * 1981-10-05 1983-04-06 Tanabe Seiyaku Co Ltd 速放性マイクロカプセル
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US5143728A (en) * 1987-09-04 1992-09-01 The Procter & Gamble Company Psyllium-containing filling compositions and methods
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5245080A (en) * 1989-02-20 1993-09-14 Jouveinal Sa (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-N-propylamine, process for preparing it and its therapeutical use
WO1992017166A1 (en) * 1991-04-08 1992-10-15 Nippon Shinyaku Co., Ltd. Capsule
WO1993015724A1 (en) * 1992-02-18 1993-08-19 Nippon Shinyaku Co., Ltd. Fast soluble tablet
WO1993023360A1 (fr) * 1992-05-12 1993-11-25 Zeria Pharmaceutical Co., Ltd. Nouveaux sels d'ammonium quaternaires et utilisation de ces sels comme medicament
MY113693A (en) * 1992-05-26 2002-05-31 Chugai Pharmaceutical Co Ltd Erythromycin derivatives having an enterokinesis stimulating action
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
ATE223704T1 (de) * 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
DE4300696A1 (de) * 1993-01-13 1994-07-14 Roemmers Sa Substituierte N-Aminoalkylmethansulfanilide als Antispasmodika
WO1994025015A1 (en) * 1993-04-28 1994-11-10 Daiichi Pharmaceutical Co., Ltd. Digestive symptom ameliorant
US5516524A (en) * 1993-12-20 1996-05-14 The Procter & Gamble Company Laxative compositions containing bulk fiber
US5486160A (en) * 1994-05-04 1996-01-23 Physion S.R.L. Device and method for the combined electropharmacological treatment of the bladder and the prostatic urethra
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
CN1063442C (zh) * 1995-05-18 2001-03-21 泽里新药工业株式会社 氨基噻唑衍生物、含有它们的药物组合物及其用途
EP0867191A4 (en) * 1995-11-27 2000-01-05 Yamanouchi Pharma Co Ltd MEDICINE COMPOSITION
US5919760A (en) * 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
CN1072652C (zh) * 1996-10-24 2001-10-10 泽里新药工业株式会社 取代的苯甲酰氨基噻唑衍生物以及含有它们的药物
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
US6022747A (en) * 1998-07-10 2000-02-08 Bayer Corporation Blood clot detector
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
JP2003501462A (ja) * 1999-06-15 2003-01-14 レスピラトリウス アクチボラゲット 受容体アゴニストおよびアンタゴニスト
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions

Also Published As

Publication number Publication date
AU2003281172A1 (en) 2004-02-02
WO2004006902A1 (en) 2004-01-22
MXPA05000477A (es) 2005-03-23
JP2005533101A (ja) 2005-11-04
US20050136127A1 (en) 2005-06-23
EP1531801A1 (en) 2005-05-25
CA2491797A1 (en) 2004-01-22
NZ537395A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
CY1115350T1 (el) Χρησεις αναστολεων της dpp iv
MX2009009207A (es) Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
MA33075B1 (fr) Composition destinee a la regulation du metabolism des lipides
MA31153B1 (fr) Composés et méthodes pour moduler une kinase et indications associées
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA33811B1 (fr) Composés et méthodes utilisés pour la modulation kinases et indications à cet effet
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA31668B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
ATE427356T1 (de) Komplementinhibitoren aus zecken
WO2007095586A3 (en) Neuronal pain pathway modulators
BR0212606A (pt) Combinação
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2064 DE 27/07/2010.